Form 4: OnKure CEO Sells Shares for Tax Obligations

OnKure Therapeutics' President and CEO, Nicholas A Saccomano, sold 87 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Nicholas A Saccomano, OnKure Therapeutics' President and CEO, sold 87 shares of Class A Common Stock.
• The transaction occurred on December 22, 2025, at a weighted average price of $2.9677 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) under the Issuer's 2023 RSU Equity Incentive Plan.
• Following this transaction, Saccomano beneficially owns 7,419 shares of Class A Common Stock.
• The reported beneficial ownership includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to equity compensation, which is a common occurrence for executives. It does not indicate a change in management's view of the company's prospects.

Positives

• The sale was a non-discretionary transaction specifically to cover tax withholding obligations, not a discretionary sale of shares.
• The reporting person, Nicholas A Saccomano, maintains substantial beneficial ownership of 7,419 shares after the transaction.

Negatives

• A slight reduction in the direct beneficial ownership of Class A Common Stock by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Management Comments

• Shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ('RSUs'), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

Industry Context

This is a routine insider transaction filing common in all industries for executives receiving equity compensation. It does not provide broader industry-specific context or trends.

Comparison to Industry Standards

• The sale of shares to cover tax withholding obligations upon RSU vesting is a standard practice for executives across various industries who receive equity-based compensation.
• This type of transaction is a common mechanism to manage tax liabilities arising from the vesting of restricted stock units, aligning with typical corporate compensation structures.

Related Party Transactions

• The transaction involves the sale of shares to cover tax obligations arising from equity compensation granted by OnKure Therapeutics to its President and CEO, Nicholas A Saccomano, which is a standard related-party dealing within compensation frameworks.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale is for tax purposes and not a discretionary divestment, suggesting no change in management's confidence.
• Employees: No direct impact mentioned, but it reflects standard equity compensation practices for executives.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of a small number of shares by the CEO to cover tax obligations associated with RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's confidence. The beneficial ownership remains substantial. Therefore, the filing itself does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate based solely on this information.

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Employee Stock Purchase Plan, ESPP, Nicholas A Saccomano, CEO, Director